Intravenous immunoglolobuline is used in the treatment of autoibulous diseases in general, autoimuscular neuromuscular diseases in particular, including immune-mediaced and peripheral nervous system disorders. Besides other treatments, thanks to its highly anti-inflammatory properties, immunoglobuline has been used for more than three decades and is considered a well-tolerated, effective way for autoimal neuropathic diseases.
1. Overview of auto auto autogive neuropath disease and immunoglobuline
Autoimful neuropathies are diseases that cause nerve and muscle damage through the mechanism of formation of autoimimmunity. This group of pathology has a very high incidence and causes defects, accounting for about half of patients with evidence of disorders of the immune system in general.
Although each individual has abnormalities in the different immune system, the most common autoimoid nerve lesions are Guillain-Barre syndrome, chronic polypynthary inflammatory disease, multi-drive motor neuron disease, and myelin-destructive peripheral neuropathic disease caused by paraproteinemia.
For autoimoid neuropathic joint diseases, those with a high circulation rate are mysthenia blemishes, Lambert-Eaton myalpathic syndrome. For muscle damage, common diseases are poly myalitis, dermatitis and buried body inflammation. In addition, some structures of the central nervous system can also be affected by self-antibodies, causing common diseases such as scattered sclerosis and hard human syndrome.
With the progress of medicine today in unraveling the process of immuno-creation in these diseases and thereby building the foundation of treatment, immunoglobuline immunoglobuline has been seen as a formal, safe way of treating autoengly and as an effective long-term therapy.
By neutralization of self-antibodies, changes in inflammatory responses, the immunoglobuline immune has somewhat limited the rate of disease progress, preventing further damage on the neuropathic muscles, improving symptoms and prolonging the quality of life of the person until there is a more radical treatment.
2. General Mechanism of Immunoglobuline Immune Activities in the Treatment of Autogive Neuropathical Diseases
There is already a lot of evidence that immunoglobuline immunes have many different mechanisms, coordinating with each other in inhibiting the pathogenescent lesions of autoimuscent neuromuscent diseases. These mechanisms may include:
2.1. Inhibition of self-antibodies
Immunoglobuline molecules act as nons specific antibodies, conducting the activation of pathogenic self-antibodies.
From there, immunoglobuline will gradually block the effects of automedic antibodies on their specific body tissue which is the pathogenic mechanism of one of the most common autoglycular neuropathic diseases, Guillain-Barre syndrome.
2.2. Inhibits additional links and prevents the formation of complexes that attack cell membranes
The effect of immunoglobuline on inhibition of additional attachments in the auto-immune system has been proven in test tubes on animal models and also in patients taking Immunoglobuline. The mechanism of Immunoglobuline in this effect is to inhibit the absorption of C3 and C4 into the endal tissues of the cell.
This is especially significant in patients with dermatitis, when the pathogenesis is caused by the deposition of complexes that attack endotry membranes.
2.3. Blockade of Fc receptors on great hencytes
The role of macro macromies is that the macroblasting, i.e. immune activity through a cell-mediates mechanism, damages tissue. When the immune immunoglobulines are transmitted to the body's 3val current, they will immediately connect through their Fc region with fcγ receptors on the grand cell.
As a result, the intermediate signaling information system of a chain of inflammatory reactions or other immune impact functions will be prevented.
2.4. Inhibition of pathogenic cytokines and other immuno-conditioning molecules
In vitro and in vivo studies have shown that immunoglobuline can help moderate reduced levels of tissue expression or reduce the circulation of cytokines and adhesion molecules.
From there, this effect will become an upstream effect during the immune damage of the disease.
3. How to take immunoglobuline in the treatment of autoglyal neuropath disease
The therapeutic dose of immunoglobuline intravenous infusion is determined emnily at 2 grams per kilogram of the patient's weight.
Although the previous treatment was to divide the total dose required for five days at a daily dose of 400 mg/kg, the preferred dosage is now to divide the total dose into two doses with each day of 1 g/kg at a time in young patients with normal renal and cardiovascular function.
The basis for this change in use is based on numerous reports that the infusion of immunoglobuline for two days does not cause more unfavorable reactions than five-day infusions, except in patients with cardiovascular disease or at high risk. Even a high dose infusion of Immunoglobuline in the short term gives a more positive treatment response.
4. Things to monitor during the use of immunoglobuline
The infusion of immunoglobulines in the treatment of autog automatically neuropathic diseases or other immune diseases can cause undesirable effects. Therefore, during the infusion process, it is necessary to closely monitor the patient for the following reactions:
4.1. Changes in viscosity and risk of thromboembolysis in serum
The immune immunoglobuline is used in the treatment of high viscosity infusions and may increase serum viscosity. This should be especially noted in patients who already have high serum viscosity factors in advance, such as those with hemolysis, hypertension or hypertension.
If the viscosity of the serum is too high, it increases the risk of thrombophrosis events and can cause acute brain stroke, pulmonary embolism or myocardial infarction.
4.2. Migraines
In patients with a history of migraine, or Migraine headache, therapy with immunoglobuline can cause an urgent pain. Fortunately, however, this migraine can be prevented by give the patient a backup drink with propranolol earlier.
In addition, the appearance of aseptic meningitis has also been noted in patients with migraine pre-encephages when transmitting immunoglobuline immunity. At the same time, immunoglobuline immunity is also believed to be associated with stroke in young women and has a history of migraines.
4.3. Aseptic meningitis
Aseptic meningitis is considered a side effect in some patients treated with immunoglobuline. This condition is not related to the immunoglobuline product, the rate of transmission or the previous pre-pathology.
When encountering aseptic meningitis after immunoglobuline infusion, the symptoms respond to strong analgesic drugs and will gradually decrease in 24 to 48 hours. At the same time, additional diagnostic tests are rarely required.
4.4. Other side effects
Similar to other biological products, after immunoglobuline infusion, patients may experience allergic symptoms such as skin reactions or, more severely, reator reactions, emergency kidney damage…
In summary, immunoglobuline therapy has long been recognized for its effectiveness in autogiling neuropathic diseases, especially when targeted therapy is not really ready. With the above level of dose and experimental use, immunoglobulines play an important role in slowing the rate of disease progress, limiting damage and maintaining body function for patients.
Auto-immune neuropathic disease causes many serious complications, which cannot be subjective. Therefore, you should treat positively, thoroughly as soon as there are signs. To register for examination and treatment at Share99 International Health Hub, you can contact Share99 Health System nationwide, or register for an online examination HERE
Reference source: nhia.org; sciencedirect.com; researchgate.net; ncbi.nlm.nih.gov; impe-qn.org.vn
SEE MORE:
- Signs of peripheral nerve pain
- Unsym causeless neurological pain
- Guillain Syndrome – Barre in Children: Things to Know
- Guillain-Barre syndrome: Causes, manifestations, treatment
- What it's like to have a nervous attack
- Glocom glaucoma :How to diagnose and treat?